Centessa Pharmaceuticals (CNTA) Competitors

Ascendis Pharma A/S (NASDAQ:ASND) and Centessa Pharmaceuticals (NASDAQ:CNTA) are both mid-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their dividends, earnings, institutional ownership, risk, community ranking, media sentiment, valuation, profitability and analyst recommendations.

Does the media prefer ASND or CNTA?

In the previous week, Ascendis Pharma A/S had 4 more articles in the media than Centessa Pharmaceuticals. MarketBeat recorded 14 mentions for Ascendis Pharma A/S and 10 mentions for Centessa Pharmaceuticals. Ascendis Pharma A/S's average media sentiment score of 0.60 beat Centessa Pharmaceuticals' score of 0.48 indicating that Ascendis Pharma A/S is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Ascendis Pharma A/S	6 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Centessa Pharmaceuticals	5 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Does the MarketBeat Community prefer ASND or CNTA?

Ascendis Pharma A/S received 410 more outperform votes than Centessa Pharmaceuticals when rated by MarketBeat users. Likewise, 66.57% of users gave Ascendis Pharma A/S an outperform vote while only 57.69% of users gave Centessa Pharmaceuticals an outperform vote.

Company	Underperform	Outperform
Ascendis Pharma A/S	Outperform Votes 440 66.57%	Underperform Votes 221 33.43%
Centessa Pharmaceuticals	Outperform Votes 30 57.69%	Underperform Votes 22 42.31%

Is ASND or CNTA more profitable?

Centessa Pharmaceuticals has a net margin of 0.00% compared to Ascendis Pharma A/S's net margin of -130.33%. Ascendis Pharma A/S's return on equity of 0.00% beat Centessa Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ascendis Pharma A/S	-130.33%	N/A	-48.77%
Centessa Pharmaceuticals	N/A	-52.13%	-38.01%

Do analysts rate ASND or CNTA?

Ascendis Pharma A/S currently has a consensus target price of $192.07, suggesting a potential upside of 48.23%. Centessa Pharmaceuticals has a consensus target price of $25.83, suggesting a potential upside of 59.37%. Given Centessa Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe Centessa Pharmaceuticals is more favorable than Ascendis Pharma A/S.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ascendis Pharma A/S	0 Sell rating(s)	1 Hold rating(s)	13 Buy rating(s)	0 Strong Buy rating(s)	2.93
Centessa Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	3.00

Do insiders and institutionals hold more shares of ASND or CNTA?

82.0% of Centessa Pharmaceuticals shares are held by institutional investors. 40.0% of Ascendis Pharma A/S shares are held by insiders. Comparatively, 11.6% of Centessa Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Which has preferable valuation & earnings, ASND or CNTA?

Centessa Pharmaceuticals has lower revenue, but higher earnings than Ascendis Pharma A/S. Ascendis Pharma A/S is trading at a lower price-to-earnings ratio than Centessa Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ascendis Pharma A/S	$288.08M	27.30	-$521.07M	-$8.08	-16.04
Centessa Pharmaceuticals	$6.85M	312.01	-$151.09M	-$1.53	-10.59

Which has more risk and volatility, ASND or CNTA?

Ascendis Pharma A/S has a beta of 0.65, meaning that its stock price is 35% less volatile than the S&P 500. Comparatively, Centessa Pharmaceuticals has a beta of 1.53, meaning that its stock price is 53% more volatile than the S&P 500.

Summary

Centessa Pharmaceuticals beats Ascendis Pharma A/S on 10 of the 18 factors compared between the two stocks.